Your browser doesn't support javascript.
loading
The application of artificial intelligence to accelerate G protein-coupled receptor drug discovery.
Nguyen, Anh T N; Nguyen, Diep T N; Koh, Huan Yee; Toskov, Jason; MacLean, William; Xu, Andrew; Zhang, Daokun; Webb, Geoffrey I; May, Lauren T; Halls, Michelle L.
Affiliation
  • Nguyen ATN; Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
  • Nguyen DTN; Department of Information Technology, Faculty of Engineering and Technology, Vietnam National University, Cau Giay, Hanoi, Vietnam.
  • Koh HY; Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
  • Toskov J; Monash Data Futures Institute and Department of Data Science and Artificial Intelligence, Monash University, Clayton, Victoria, Australia.
  • MacLean W; Monash DeepNeuron, Monash University, Clayton, Victoria, Australia.
  • Xu A; Monash DeepNeuron, Monash University, Clayton, Victoria, Australia.
  • Zhang D; Monash DeepNeuron, Monash University, Clayton, Victoria, Australia.
  • Webb GI; Drug Discovery Biology Theme, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia.
  • May LT; Monash Data Futures Institute and Department of Data Science and Artificial Intelligence, Monash University, Clayton, Victoria, Australia.
  • Halls ML; Monash Data Futures Institute and Department of Data Science and Artificial Intelligence, Monash University, Clayton, Victoria, Australia.
Br J Pharmacol ; 2023 May 10.
Article in En | MEDLINE | ID: mdl-37161878
The application of artificial intelligence (AI) approaches to drug discovery for G protein-coupled receptors (GPCRs) is a rapidly expanding area. Artificial intelligence can be used at multiple stages during the drug discovery process, from aiding our understanding of the fundamental actions of GPCRs to the discovery of new ligand-GPCR interactions or the prediction of clinical responses. Here, we provide an overview of the concepts behind artificial intelligence, including the subfields of machine learning and deep learning. We summarise the published applications of artificial intelligence to different stages of the GPCR drug discovery process. Finally, we reflect on the benefits and limitations of artificial intelligence and share our vision for the exciting potential for further development of applications to aid GPCR drug discovery. In addition to making the drug discovery process "faster, smarter and cheaper," we anticipate that the application of artificial intelligence will create exciting new opportunities for GPCR drug discovery.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Br J Pharmacol Year: 2023 Document type: Article Affiliation country: Australia Country of publication: Reino Unido

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Br J Pharmacol Year: 2023 Document type: Article Affiliation country: Australia Country of publication: Reino Unido